Skip to main
VCEL
VCEL logo

Vericel (VCEL) Stock Forecast & Price Target

Vericel (VCEL) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Vericel Corp is positioned for robust growth, particularly with its MACI product, which is projected to achieve a year-over-year revenue increase of approximately 21.2% in FY26, driven by a combination of volume growth and annual average selling price (ASP) increases. The company anticipates a significant rise in quarterly revenue, with 4Q expectations reaching $84.8 million, reflecting a 26% quarter-over-quarter growth. Additionally, the sustained growth in MACI's revenues, supported by a compound annual growth rate (CAGR) of 14.8% in volume alongside an annual ASP growth of 300 to 500 basis points, lays a solid foundation for long-term financial performance.

Bears say

Vericel Corp has revised its revenue expectations for its MACI product downward by approximately 200 basis points for fiscal years 2026 and 2027, indicating potential challenges in meeting previous forecasts. Key financial risks include lower than anticipated uptake of MACI Arthro, slower sales growth in the burn care segment, and the possibility of operational disruptions due to sales force expansion efforts. Additionally, uncertainties surrounding physician adoption rates for MACI, inconsistent usage of Epicel among burn patients, and delays in NexoBrid's approval contribute to a pessimistic outlook, with potential repercussions on share valuation if quarterly top-line expectations are missed.

Vericel (VCEL) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Vericel and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Vericel (VCEL) Forecast

Analysts have given Vericel (VCEL) a Strong Buy based on their latest research and market trends.

According to 4 analysts, Vericel (VCEL) has a Strong Buy consensus rating as of Dec 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $58.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $58.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Vericel (VCEL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.